Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(2):132-141; doi:10.1093/jnci/dji011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bianco, C.
Right arrow Articles by Salomon, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bianco, C.
Right arrow Articles by Salomon, D. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

ARTICLE

Role of Human Cripto-1 in Tumor Angiogenesis

Caterina Bianco, Luigi Strizzi, Andreas Ebert, Cindy Chang, Aasia Rehman, Nicola Normanno, Liliana Guedez, Rita Salloum, Erika Ginsburg, Youping Sun, Nadia Khan, Morihisa Hirota, Brenda Wallace-Jones, Christian Wechselberger, Barbara K. Vonderhaar, Giovanna Tosato, William G. Stetler-Stevenson, Michele Sanicola, David S. Salomon

Affiliations of authors: Tumor Growth Factor Section, Mammary Biology and Tumorigenesis Laboratory (CB, LS, CC, YS, NK, MH, BW-J), Molecular and Cellular Endocrinology Section, Mammary Biology and Tumorigenesis Laboratory (EG, BKV), Extracellular Matrix Section, Laboratory of Pathology (LG, RS, WGS-S), Experimental Transplantation and Immunology Branch (GT), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Gynecology, Charite Campus Benjamin Franklin, Berlin, Germany (AE); Department of Molecular and Cellular Biology, University of Michigan, Ann Arbor, MI (AR); Division of Haematological Oncology and Department of Experimental Oncology, ITN-Fondazione Pascale, Naples, Italy (NN); Upper Austrian Research GmbH Zentrum, Linz, Austria (CW); Biogen-Idec Inc., Cambridge, MA (MS)

Correspondence to: David S. Salomon, PhD, Tumor Growth Factor Section, Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg. 10, Rm. 5B39, Bethesda, MD 20892 (e-mail: salomond{at}mail.nih.gov)

Background: Human cripto-1 (CR-1) promotes cell transformation and increases migration and invasion of various mouse and human epithelial cell lines. We investigated whether CR-1 also stimulates angiogenesis. Methods: We used human umbilical vein endothelial cells (HUVECs) to measure in vitro migration with fibronectin-coated Boyden chambers, invasion with Matrigel-coated Boyden chambers, proliferation with a tetrazolium salt, and differentiation with an in vitro Matrigel assay. We investigated new blood vessel formation in vivo by use of Matrigel-filled silicone cylinders implanted under the skin of nude mice and by use of a breast cancer xenograft model with CR-1-transfected or control Neo-transfected MCF-7 human breast cancer cells. We also used a blocking anti-CR-1 monoclonal antibody to investigate the role of CR-1 in angiogenesis in vivo and in vitro. All statistical tests were two-sided. Results: CR-1 stimulated HUVEC proliferation, migration, and invasion and induced HUVEC differentiation into vascular-like structures on Matrigel. In vivo, recombinant CR-1 protein induced microvessel formation in Matrigel-filled silicone cylinders, and microvessel formation was statistically significantly inhibited with a blocking anti-CR-1 monoclonal antibody (CR-1 and antibody = 127% of microvessel formation compared with that in untreated control cylinders and CR-1 alone = 259%; difference = 132%, 95% confidence interval [CI] = 123% to 140%; P<.001). Tumors formed by CR-1-transfected MCF-7 cells in the cleared mammary fat pad of nude mice had higher microvessel density than tumors formed by control Neo-transfected MCF-7 cells (CR-1-transfected cells = 4.66 vessels per field and Neo-transfected cells = 2.33 vessels per field; difference = 2.33 vessels per field, 95% CI = 1.2 to 2.8; P = .004). Conclusion: CR-1 appears to have an important role in the multistep process of angiogenesis.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
C. Bianco, L. Strizzi, M. Mancino, K. Watanabe, M. Gonzales, S. Hamada, A. Raafat, L. Sahlah, C. Chang, F. Sotgia, et al.
Regulation of Cripto-1 Signaling and Biological Activity by Caveolin-1 in Mammary Epithelial Cells
Am. J. Pathol., February 1, 2008; 172(2): 345 - 357.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Watanabe, C. Bianco, L. Strizzi, S. Hamada, M. Mancino, V. Bailly, W. Mo, D. Wen, K. Miatkowski, M. Gonzales, et al.
Growth Factor Induction of Cripto-1 Shedding by Glycosylphosphatidylinositol-Phospholipase D and Enhancement of Endothelial Cell Migration
J. Biol. Chem., October 26, 2007; 282(43): 31643 - 31655.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Hentschke, I. Kurth, U. Borgmeyer, and C. A. Hubner
Germ Cell Nuclear Factor Is a Repressor of CRIPTO-1 and CRIPTO-3
J. Biol. Chem., November 3, 2006; 281(44): 33497 - 33504.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Bianco, L. Strizzi, M. Mancino, A. Rehman, S. Hamada, K. Watanabe, A. De Luca, B. Jones, G. Balogh, J. Russo, et al.
Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer
Clin. Cancer Res., September 1, 2006; 12(17): 5158 - 5164.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.